<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>In-situ priming expands TRM and clonal breadth to sterilize micrometastases - Theorizer</title>
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.15.1/css/all.min.css">
    <link rel="stylesheet" href="../style.css">
</head>
<body>
    <div class="header">
        <a href="../index.html"><i class="fas fa-flask"></i> Theorizer</a>
    </div>

    <div class="content">
        <h1>Theory Details for theory-22</h1>

        <div class="section">
            <h2>Theory (General Information)</h2>
            <div class="info-section">
                <p><strong>ID:</strong> theory-22</p>
                <p><strong>Name:</strong> In-situ priming expands TRM and clonal breadth to sterilize micrometastases</p>
                <p><strong>Type:</strong> general</p>
                <p><strong>Theory Query:</strong> Build a theory of why neoadjuvant-plus-adjuvant immunotherapy improves melanoma outcomes compared to adjuvant-only immunotherapy, based on the following results.</p>
                <p><strong>Description:</strong> Initiating checkpoint blockade while tumor is in place activates tissue-resident memory T cells (TRM) locally and recruits circulating T cells, expanding the breadth and persistence of tumor-reactive clones. TRM–dendritic cell crosstalk triggers antigen spreading, amplifying systemic immunity that sterilizes micrometastases. This cell-biological mechanism underlies improved clinical outcomes of neoadjuvant-plus-adjuvant over adjuvant-only therapy.</p>
                <p><strong>Knowledge Cutoff Year:</strong> 2029</p>
                <p><strong>Knowledge Cutoff Month:</strong> 12</p>
                <p><strong>Base Model:</strong> openai/gpt-5</p>
            </div>
        </div>
        </div>

        <div class="section">
            <h2>Theory (Statement/Laws)</h2>

            <h3>Theory Statements/Laws</h3>
            <hr/>
            <h3>Statement 0: Law 0</h3>
            <p><strong>Statement:</strong> None</p>
            <p><strong>Domain/Scope:</strong> <span class="empty-note">Not specified.</span></p>
            <h4>Special Cases</h4>
            <h4>Supporting Evidence for this Law</h4>
<p class="empty-note">No evidence provided.</p>            <h4>Self-Evaluation of Law Novelty (produced by the generation model)</h4>
            <p><strong>Likely Classification:</strong> unknown</p>
        <p><strong>Explanation:</strong> No explanation provided.</p>
        <p><strong>References:</strong> <span class="empty-note">No references provided.</span>            <h4>External Evaluations of this Law</h4>
            <p><strong>Predictive Accuracy Evaluation:</strong> <span class="empty-note">Not available.</span></p>
            <p><strong>Novelty Evaluation:</strong> <span class="empty-note">Not available (available only for a randomly selected subset of 100 laws, due to cost).</span></p>
            <hr/>
            <h3>Statement 1: Law 1</h3>
            <p><strong>Statement:</strong> None</p>
            <p><strong>Domain/Scope:</strong> <span class="empty-note">Not specified.</span></p>
            <h4>Special Cases</h4>
            <h4>Supporting Evidence for this Law</h4>
<p class="empty-note">No evidence provided.</p>            <h4>Self-Evaluation of Law Novelty (produced by the generation model)</h4>
            <p><strong>Likely Classification:</strong> unknown</p>
        <p><strong>Explanation:</strong> No explanation provided.</p>
        <p><strong>References:</strong> <span class="empty-note">No references provided.</span>            <h4>External Evaluations of this Law</h4>
            <p><strong>Predictive Accuracy Evaluation:</strong> <span class="empty-note">Not available.</span></p>
            <p><strong>Novelty Evaluation:</strong> <span class="empty-note">Not available (available only for a randomly selected subset of 100 laws, due to cost).</span></p>
            <hr/>
            <h3>Statement 2: Law 2</h3>
            <p><strong>Statement:</strong> None</p>
            <p><strong>Domain/Scope:</strong> <span class="empty-note">Not specified.</span></p>
            <h4>Special Cases</h4>
            <h4>Supporting Evidence for this Law</h4>
<p class="empty-note">No evidence provided.</p>            <h4>Self-Evaluation of Law Novelty (produced by the generation model)</h4>
            <p><strong>Likely Classification:</strong> unknown</p>
        <p><strong>Explanation:</strong> No explanation provided.</p>
        <p><strong>References:</strong> <span class="empty-note">No references provided.</span>            <h4>External Evaluations of this Law</h4>
            <p><strong>Predictive Accuracy Evaluation:</strong> <span class="empty-note">Not available.</span></p>
            <p><strong>Novelty Evaluation:</strong> <span class="empty-note">Not available (available only for a randomly selected subset of 100 laws, due to cost).</span></p>
            <hr/>
        </div>
        <div class="section">
            <h2>Theory (Additional Details)</h2>
                        <h3>New Predictions (Likely outcome)</h3>
            <ol>
                <li>Greater intratumoral TRM density and PD-1/LAG-3 co-expression at baseline will correlate with higher MPR after neoadjuvant PD-1±LAG-3 and superior 2-year RFS.</li>
                <li>Breadth of TCR clonotypes expanding between pre-dose and 3 weeks post–neoadjuvant PD-1 will predict MPR and EFS independent of radiographic response.</li>
                <li>Markers of antigen processing/presentation (e.g., DC activation signatures) in pre-op samples will associate with post-op ctDNA negativity and improved DMFS.</li>
            </ol>
            <h3>New Predictions (Unknown outcome/high-entropy)</h3>
            <ol>
                <li>Augmenting TRM–DC crosstalk with intratumoral DC agonists (e.g., CD40/TLR) during neoadjuvant PD-1 will increase antigen spreading, raising MPR and long-term EFS.</li>
                <li>Short-course neoadjuvant LAG-3+PD-1 will preferentially expand exhausted-TRM progenitors (TOXhi) linked to superior durability compared with PD-1 alone.</li>
                <li>Ex vivo TRM functional assays from pre-op tumor will predict micrometastatic sterilization better than bulk RNA signatures.</li>
            </ol>
            <h3>Negative Experiments</h3>
            <ol>
                <li>Failure to observe early TRM/circulating T-cell activation after neoadjuvant PD-1, coupled with no EFS difference vs adjuvant-only, would challenge the TRM-centric mechanism.</li>
                <li>Lack of TCR breadth expansion or antigen spreading signals in responders would argue against the proposed broadening mechanism.</li>
            </ol>
            <h3>Unaccounted for Evidence</h3>
<ol>
    <li>Direct human causal evidence linking TRM–DC antigen spreading to patient-level EFS is inferential; mechanistic surrogates are correlative. </li>
</ol>        </div>        <div style="height: 30px;"></div>
    </div>
</body>
</html>